Summary
Tissue plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1) and von Willebrand factor (vWF), all of endothelial origin and active in the haemostasis, were analysed in 74 patients with rheumatoid arthritis. The concentrations were related to extra-articular disease and to the incidence of thromboembolic events (TE) registered in a 2-year follow-up period. Patients with extra-articular disease had a significant increase in PAI-1 activity and reduced tPA release in the venous occlusion test. von Willebrand factor, PAI-1 and also haptoglobin and triglycerides were significantly increased in the group of patients who later suffered from TE. In a multiple regression model, in which cholesterol, triglycerides and lipoprotein (a) showed significant association with TE, vWF had the strongest additive explanatory value. No distinct acute phase pattern of PAI-1 was found in any patient subgroup.
References
Bachmann, F. Fibrinolysis. In: Thrombosis and Haemostasis 1987. Eds.: Verstraete, M., Vermylen, J., Lijnen, H.R., Arnout, J., Leuven University Press Leuven, 1987, 227–265.
Rijken, D.C., Wijngards, G., Welbergen, J. Relationship between tissue plasminogen activator and the activators in blood and vascular wall. Thromb Res 1980, 18, 815–830.
Dosne, A.M., Dupuy, E., Bedevin, E. Production of a fibrinolytic inhibitor by cultured endothelial cells derived from human umbilical vein. Thromb Res 1978, 12, 377–387.
Jaffe, E.A., Hoyer, L.W., Nachman, R.L. Synthesis of von Willebrand factor by cultured human endothelial cells. Proc Natl Acad Sci 1974, 71, 1906–1909.
Hart, D.A., Fritzler, M.J. Regulation of plasminogen activators and their inhibitors in rheumatic diseases: New understanding and the potential for new directions. J Rheumatol 1989, 16, 1184–1191.
Jordan, J.M., Bates Allen, N., Pizzo S.V. Defective release of tissue plasminogen activator in systemic and cutaneous vasculitis. Am J Med 1987, 82, 397–400.
Belch, J.J.F., Mc Ardle, B., Madhok, R., McLaughlin, K., Capell, H.A., Forbes, C.D., Sturrock, R.D. Decreased plasma fibrinolysis in patients with rheumatoid arthritis. Ann Rheum Dis 1984, 43, 774–777.
van de Putte, L.B.A., Noordhoek Hegt, V., Overbeek, T.A. Activators and inhibitors of fibrinolysis in rheumatoid and nonrheumatoid synovial membranes. Arthritis Rheum 1977, 20, 671–678.
Kikuchi, H., Tanaka, S., Matsuo, O. Plasminogen activators in synovial fluid from patients with rheumatoid arthritis. J Rheumatol 1987, 14, 439–445.
Mussoni, L., Pintucci, G., Romano, G., De Benedetti, F., Massa, M., Martini, A. Decreased fibrinolytic activity in juvenile chronic arthritis. Ann Rheum Dis 1990, 49, 973–975.
Belch, J.J.F., Zoma, A.A., Richards, I.M., McLaughlin, K., Forbes, C.D., Sturrock, R.D. Vascular damage and factor VIII related antigen in the rheumatic diseases. Rheumatol Im 1987, 7; 107–111.
Nusinow, S.R., Federici, A.B., Zimmerman, T.S., Curd, J.G. Increased von Willebrand factor antigen in the plasma of patients with vasculitis. Arthritis Rheum 1984, 27, 1405–1410.
Bleil, L., Manger, B., Winkler, T.H., Herrman, M., Burmester, G.R., Krapf, F.E., Kalden, J.R. The role of antineutrophil cytoplasm antibodies, anticardiolipin antibodies, von Willebrand factor antigen, and fibronectin for the diagnosis of systemic vasculitis. J Rheumatol 1991, 18, 1199–1206.
Jansson, J.H. The fibrinolytic system in ischaemic heart disease. In: Nilsson, T.K., Boman, K., Jansson, J.H., Clinical Aspects on Fibrinolysis. Ed.: Almqvist & Wiksell International, Stockholm 1991, 95–110.
Hamsten, A., Wiman, B., De Faire, U., Blombäck, M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985, 313, 1557–1563.
Nilsson, I.M., Ljungnér, H., Tengborn, L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentrations of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J 1985, 290, 1453–1456.
Wahlberg, T., Blombäck, M., Övermark, I. Blood coagulation studies in 45 patients with ischemic cerebrovascular disease and 44 patients with venous thromboembolic disease. Acta Med Scand 1980, 207, 385–390.
Schmitz-Huebner, U., Thompson, S.G., Balleisen, L., Fechtrup, C., Grosse-Heitmeyer, W., Kirchhof, B., Most, E., Müller, U.S., Seiffert, C., Seiffert, D., van de Loo, J. Lack of association between haemostatic variables and the presence or extent of coronary atherosclerosis. Br Heart J 1988, 59, 287–291.
Hamsten, A., Walldius, G., Szamosi, A., Blombäck, M., de Faire, U., Dahlén, G., Landou, C., Wiman, B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987, ii, 3–8.
Jansson, J.H., Nilsson, T.K., Olofsson, B.O. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 1991, 12, 157–161.
Jansson, J.H., Nilsson, T.K., Johnson, O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991, 66, 351–355.
Isomäki, H.A., Mutru, O., Koota, K. Death rate and causes of death in patients with rheumatoid arthritis. Scand J Rheumatol 1975, 4, 205–208.
Allebeck, P., Ahlbom, A., Allander, E. Increased mortality among patients with rheumatoid arthritis, but where RA does not appear on death certificate. Scand J Rheumatol 1981, 10, 301–306.
Reilly, P.A., Cosh, J.A., Maddison, P.J., Rasker, J.J., Silman, A.J. Mortality and survival in rheumatoid arthritis: a 25-year prospective study of 100 patients. Ann Rheum Dis 1990, 49, 363–369.
Rantapää-Dahlqvist, S., Wållberg-Jonsson, S., Dahlén, G.H. Lipoprotein (a), lipids and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis 1991, 50, 366–368.
Ropes, M.W., Bennett, G.A., Cobb, S. Diagnostic criteria for rheumatoid arthritis. Ann Rheum Dis 1959, 18, 49–53.
Cooperating Clinics Committee of the American Rheumatism Association: A seven day variability study of 499 patients with peripheral rheumatoid arthritis. Arthritis Rheum 1965, 8, 302–334.
Dahlén, G.H. Lipoprotein (a) in relation to atherosclerotic diseases. In: Prog Clin Biol Res. Eds.: Widhalm, K., Naito, H.K., 1988, 255, 27–36.
Wiman, B., Mellbring, G., Rånby, M. Plasminogen activator release during venous stasis and exercise as determined by a new specific assay. Clin Chem Acta 1983, 127, 279–288.
Eriksson, E., Rånby, M., Gyzander, E., Risberg, B. Determination of plasminogen activator inhibitor in plasma using tPA and a chromogenic single-point poly-D-lysine stimulated assay. Thromb Res 1988, 50, 91–101.
Cejka, J. Enzyme immunoassay for factor VIII-related antigen. Clin Chem 1982, 28, 1356–1358.
Rånby, M., Sundell, I.B., Johnson, O., Ledin, M-C, Dahlén G. Activity of plasminogen activator inhibitor-1 (PAI-1) in a population of northern Sweden. Fibrinolysis 1990, 2, 54–55.
Lau, C.S., McLaren, M., Hanslip, J., Morley, K.D., Belch, J.J.F. Abnormal fibrinolytic response in patients with rheumatoid arthritis complicated by vasculitis. Br J Rheum 1991, Abstracts suppl: 68.
Angles-Cano, E., Sultan, Y., Cluvel, J.P. Predisposing factors to thrombosis in systemic lupus erythematosus. J Lab Clin Med 1979, 94, 313–323.
Nilsson, T.K., Norberg, B., Wållberg-Jonsson, S., Rantapää-Dahlqvist, S. von Willebrand factor in plasma as risk factor for cardiovascular events. J Int Med 1991, 229, 557–558.
Juhan-Vague, I., Alessi, M.C., Vague, P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991, 34, 457–462.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wållberg-Jonsson, S., Dahlén, G.H., Nilsson, T.K. et al. Tissue plasminogen activator, plasminogen activator inhibitor-1 and von willebrand factor in rheumatoid arthritis. Clin Rheumatol 12, 318–324 (1993). https://doi.org/10.1007/BF02231572
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02231572